| Gene Symbol | GFAP |
| Full Name | Guided Astrocyte Modulation Therapy |
| Aliases | Glial Fibrillary Acidic Protein Gene, Glial Fibrillary Acidic Protein |
| Chromosome | 17q21.31 |
| Protein Family | Type III intermediate filament protein |
| Protein Type | Biomarker / Structural Protein |
| Target Class | Structural Protein |
| Function | Biomarker readout — GFAP levels reflect astrocyte reactivity; modulating upstream pathways (e.g., NF-κB, JAK-STAT) reduces GFAP expression |
| Mechanism of Action | Biomarker readout — GFAP levels reflect astrocyte reactivity; modulating upstream pathways (e.g., NF-κB, JAK-STAT) reduces GFAP expression |
| Primary Expression | Cytoplasm (cytoskeletal intermediate filament) |
| Druggability | Medium (0.52) |
| Clinical Stage | Phase II |
| Molecular Weight | 50 kDa |
| Amino Acids | 432 aa |
| Exons | 9 |
| Pathways | Amyloid, Er Stress, Inflammasome, Innate Immunity, Mapk |
| UniProt ID | P14136 |
| GeneCards | GFAP |
| Human Protein Atlas | GFAP |
| Associated Diseases | ALEXANDER_DISEASE, ALS, ALZHEIMER'S DISEASE, ALZHEIMER_DISEASE, ASTROGLIAL_ACTIVATION, AXONAL DEGENERATION |
| Known Drugs/Compounds | METFORMIN, VANADIUM, TMT, PHENYTOIN, DSS, Hormones |
| Interactions | MMP9, TNF, TLR4, MMP2, TMEM119, NFL |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Heterogeneous astrocyte activation states differen GFAP-Positive Reactive Astrocyte Subtype Delineati |
| KG Connections | 3103 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |